ANI Pharma (ANIP) Tops Q1 EPS by 15c; Suspends FY20 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Tech stocks pull Wall Street lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
ANI Pharmaceuticals Reports First Quarter 2020 Results and Appoints Interim CEO
May 7, 2020 8:30 AM EDTBAUDETTE, Minn., May 7, 2020 /PRNewswire/ --
For the first quarter 2020, ANI reports:
Net revenues of $49.8 million versus $52.9 million in 2019 GAAP net loss of $7.0 million and diluted GAAP loss per share of $0.59 Adjusted non-GAAP EBITDA of $17.6 million Adjusted non-GAAP diluted earnings per share of $1.04Integrates Amerigen Pharmaceuticals, Ltd. portfolio
Launches five generic products increasing total commercialized product line to 60 product families
Appoints Patrick D. Walsh interim President and CEO
Suspends guidance for 2020
ANI Pharmaceuticals, Inc.... More
